{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:34:50Z","timestamp":1793057690308,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000},"content-version":"vor","delay-in-days":127,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02095-4","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:26:20Z","timestamp":1782134780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer\u2019s disease: a target trial emulation"],"prefix":"10.1186","volume":"18","author":[{"given":"Chuo-Yu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ya","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-1251","authenticated-orcid":false,"given":"Tien-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"2","key":"2095_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"key":"2095_CR2","doi-asserted-by":"publisher","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;2006(1):CD005593. https:\/\/doi.org\/10.1002\/14651858.CD005593.\u00a0PMID: 16437532; PMCID: PMC9006343.","DOI":"10.1002\/14651858.CD005593"},{"issue":"2","key":"2095_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1872208316666220302115901","volume":"16","author":"M Saeedi","year":"2022","unstructured":"Saeedi M, Mehranfar FJRpob. Challenges and approaches of drugs such as memantine, donepezil, rivastigmine, and aducanumab in the treatment, control and management of Alzheimer\u2019s disease. Recent Pat Biotechnol. 2022;16(2):102\u201321.","journal-title":"Recent Pat Biotechnol"},{"issue":"1","key":"2095_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"L-K Huang","year":"2023","unstructured":"Huang L-K, et al. Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci. 2023;30(1):83.","journal-title":"J Biomed Sci"},{"issue":"1","key":"2095_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"2095_CR6","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.tjpad.2025.100195","volume":"1","author":"CW Hsu","year":"2025","unstructured":"Hsu CW, et al. The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis. JPAD-J PREV ALZHEIM. 2025;1:100195.","journal-title":"JPAD-J PREV ALZHEIM"},{"issue":"2","key":"2095_CR7","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035.","journal-title":"JAMIA Open"},{"issue":"2","key":"2095_CR8","doi-asserted-by":"publisher","first-page":"e70080","DOI":"10.1002\/trc2.70080","volume":"11","author":"X Li","year":"2025","unstructured":"Li X, et al. Generating real\u2010world evidence in early Alzheimer\u2019s disease: considerations for applying the target trial emulation framework to study the safety of anti\u2010amyloid therapies. Alzheimers Dement (N Y). 2025;11(2):e70080.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"2095_CR9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","volume":"334","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, et al. Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement. JAMA. 2025;334(12):1084\u201393.","journal-title":"JAMA"},{"issue":"8","key":"2095_CR10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JMJAjoe. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"key":"2095_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EBJFin. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"issue":"11","key":"2095_CR12","first-page":"3595","volume":"24","author":"SJ Zawada","year":"2024","unstructured":"Zawada SJ, et al. Feasibility of observing cerebrovascular disease phenotypes with smartphone monitoring: study design considerations for real-world studies. QJM. 2024;24(11):3595.","journal-title":"QJM"},{"issue":"2","key":"2095_CR13","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1093\/geront\/gnx202","volume":"58","author":"AN Leggett","year":"2018","unstructured":"Leggett AN, et al. Falls and hospitalizations among persons with dementia and associated caregiver emotional difficulties. Gerontologist. 2018;58(2):e78\u201386.","journal-title":"Gerontologist"},{"issue":"1","key":"2095_CR14","doi-asserted-by":"publisher","first-page":"e2249950","DOI":"10.1001\/jamanetworkopen.2022.49950","volume":"6","author":"CH Ormseth","year":"2023","unstructured":"Ormseth CH, et al. Predisposing and precipitating factors associated with delirium: a systematic review. JAMA Netw Open. 2023;6(1):e2249950.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2095_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding PJAoim. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2095_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/pds.1946","volume":"19","author":"JE Amuah","year":"2010","unstructured":"Amuah JE, et al. Persistence with cholinesterase inhibitor therapy in a population\u2010based cohort of patients with Alzheimer\u2019s disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2095_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2095_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):105.","journal-title":"Alzheimers Res Ther"},{"key":"2095_CR19","doi-asserted-by":"publisher","first-page":"862369","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RSJFiN. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease. Front Neurol. 2022;13:862369.","journal-title":"Front Neurol"},{"key":"2095_CR20","doi-asserted-by":"publisher","first-page":"1559447","DOI":"10.3389\/fphar.2025.1559447","volume":"16","author":"L Yan","year":"2025","unstructured":"Yan L, et al. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for Lecanemab. Front Pharmacol. 2025;16:1559447.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2095_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, et al. Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):119.","journal-title":"Alzheimers Res Ther"},{"key":"2095_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-025-00756-4","volume":"14","author":"MN Sabbagh","year":"2025","unstructured":"Sabbagh MN, et al. Characterizing the Journey of Early Alzheimer\u2019s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study. Neurol Ther. 2025;14:1\u201313.","journal-title":"Neurol Ther"},{"key":"2095_CR23","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/fphar.2023.1161850","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra M, et al. Revisiting the neuroinflammation hypothesis in Alzheimer\u2019s disease: a focus on the druggability of current targets. Front Pharmacol. 2023;14:1161850.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2095_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000316530","volume":"8","author":"D Sehlin","year":"2011","unstructured":"Sehlin D, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-A\u03b2 antibodies. Neurodegener Dis. 2011;8(3):117\u201323.","journal-title":"Neurodegener Dis"},{"issue":"8","key":"2095_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","volume":"168","author":"CL Vigen","year":"2011","unstructured":"Vigen CL, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831\u20139.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"2095_CR26","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"Society, A.G.S.B.C.U.E.P.J.J.o.t.A.G.","year":"2023","unstructured":"Society, A.G.S.B.C.U.E.P.J.J.o.t.A.G. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052\u201381.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2095_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cger.2012.01.002","volume":"28","author":"BM Shah","year":"2012","unstructured":"Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28(2):173\u201386.","journal-title":"Clin Geriatr Med"},{"key":"2095_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.exger.2018.02.011","volume":"106","author":"C Mueller","year":"2018","unstructured":"Mueller C, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240\u20135.","journal-title":"Exp Gerontol"},{"issue":"8","key":"2095_CR29","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/j.1532-5415.2010.02924.x","volume":"58","author":"JL Rudolph","year":"2010","unstructured":"Rudolph JL, et al. Hospitalization in community\u2010dwelling persons with Alzheimer\u2019s disease: frequency and causes. J Am Geriatr Soc. 2010;58(8):1542\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2095_CR30","doi-asserted-by":"publisher","first-page":"105346","DOI":"10.1016\/j.jamda.2024.105346","volume":"26","author":"H J\u00e4rvinen","year":"2025","unstructured":"J\u00e4rvinen H, Tolppanen AM, Hartikainen S. Hospitalization Due to Infections before and after Alzheimer\u2019s Disease Diagnosis. J Am Med Dir Assoc. 2025;26(1):105346.","journal-title":"J Am Med Dir Assoc"},{"issue":"7","key":"2095_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jamda.2020.12.021","volume":"22","author":"A Hakala","year":"2021","unstructured":"Hakala A, et al. Does recent hospitalization increase antipsychotic initiation among community dwellers with Alzheimer\u2019s disease? J Am Med Dir Assoc. 2021;22(7):1543-1547. e3.","journal-title":"J Am Med Dir Assoc"},{"issue":"12","key":"2095_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.7326\/0003-4819-156-12-201206190-00005","volume":"156","author":"TG Fong","year":"2012","unstructured":"Fong TG, et al. Adverse outcomes after hospitalization and delirium in persons with Alzheimer disease. Ann Intern Med. 2012;156(12):848\u201356.","journal-title":"Ann Intern Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02095-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02095-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02095-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:30:04Z","timestamp":1793057404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02095-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02095-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Kaohsiung Medical University Hospital Institutional Review Board (KMUHIRB-E(I)-20250199). The requirement for informed consent was waived because the study used deidentified electronic health record data from the TriNetX network.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript contains no individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"236"}}